Ep 51 Why Researchers Continue Studying Dezawa MuseCells® Across Multiple Medical Fields

Welcome back to the show. Today we’re taking a closer look at a naturally occurring stem cell that keeps showing up in research papers across a surprising range of medical specialties: the Muse cell, discovered in 2010 by Professor Mari Dezawa and her colleagues at Tohoku University.

What makes this cell type so interesting to scientists isn’t just that it’s pluripotent-like, meaning it has the potential to become many different cell types. It’s that Muse cells appear to know where to go. They carry a receptor called S1PR2, which detects a signaling molecule released by damaged tissue, called sphingosine-1-phosphate. When tissue anywhere in the body is injured, Muse cells circulating in the blood can sense that signal and travel toward it. That mechanism isn’t specific to any one organ, which helps explain why researchers in neurology, cardiology, orthopedics, pulmonology, and dermatology have each, independently, started investigating the same cell type.

In neurology, scientists have looked at how Muse cells behave after stroke and spinal cord injury. In cardiology, researchers have studied whether these cells home to heart tissue after a heart attack, and whether they can differentiate into the kinds of cells that make up heart muscle and blood vessels. Some of that cardiology work has moved into early-phase human trials, largely in Japan, alongside similar early trials for conditions like ALS, spinal cord injury, and a genetic skin condition called epidermolysis bullosa. Orthopedic and pulmonary research remains earlier stage, still largely limited to laboratory and animal studies.

It’s worth pausing here to be clear about what all of this does and doesn’t mean. Early-phase clinical trials are designed to answer questions about safety and dosing. They are not the same as full regulatory approval, and no Muse cell-based product currently holds that kind of approval for routine use in the United States. Anything you hear described in the research literature should be understood as investigational unless a specific regulatory clearance is cited.

So why does it matter that so many different fields are studying the same cell independently? Because when neurologists, cardiologists, and dermatologists are all seeing similar patterns, it strengthens the overall case for the underlying biological mechanism, even while each specialty is still working through its own condition-specific questions. Researchers tend to track a similar set of themes across this work: how precisely the cells home to an injury site, whether they reliably turn into the right kind of tissue once they arrive, how dosing and repeat administration affect outcomes, and what the long-term safety picture looks like.

Organizations like STEMS Health, a regenerative medicine practice based in Miami Beach, Florida, follow this research closely as part of staying current on where the science stands. If you’re curious about Muse cell research, it’s a field worth watching, and one that’s likely to keep generating new questions for years to come.

That’s it for today’s episode. Thanks for listening.